66 Chapter 3 Baseline definition of migraine days Using migraine characteristics with a duration of ≥4 hours led to a total sum of 91,407 migraine days, on which a triptan was used in 34.0% (n=31,071 days) of these days. Adding days defined by triptan intake alone (n=15,023 days) led to a total sum of baseline migraine days of n=106,430 days (Figure 1). Patients with migraine with aura (MA) had a total of n=10,171 migraine days with visual aura symptoms lasting 5 to 60 minutes. Of these migraine days with aura, 8.5% (n=860) were days with aura without a headache present. Table 2. Baseline characteristics of study population. CM HFEM LFEM Total Number of patients, n 283 731 480 1,494 Years of age, mean ± SD 43.5 ± 12.7 44.0 ± 12.0 41.8 ± 10.7 43.2 ± 11.8 Female sex, n (%) 225 (79.5) 655 (89.5) 435 (90.6) 1,315 (88.0) Migraine with aura, n (%) 118 (41.7) 248 (33.9) 188 (39.2) 554 (37.1) Diary compliance/montha, n (%) 27.2 (97.1) 27.1 (96.7) 27.3 (97.4) 27.1 (97.0) Migraine days/month, mean ± SD 13.7 ± 5.5 6.9 ± 2.7 2.9 ± 1.6 6.9 ± 4.9 Headache days/monthb, mean ± SD 19.8 ± 5.3 10.5 ± 4.5 6.9 ± 4.1 11.1 ± 6.4 Acute medication days/month, mean ± SD 6.6 ± 4.6 6.2 ± 3.2 4.7 ± 3.1 5.8 ± 3.6 Analgesic days/month, mean ± SD 4.3 ± 4.7 3.5 ± 3.4 3.7 ± 3.3 3.7 ± 3.7 Triptan days/month, mean ± SD 3.6 ± 3.4 3.8 ± 2.6 1.5 ± 1.5 3.0 ± 2.7 MOH, n (%) 78 (27.6) 5 (0.7) 0 (0.0) 83 (5.6) a. Months are defined as periods of 28 days. b. Headache days also include migraine days. CM = Chronic migraine is defined as ≥ 3 consecutive months with ≥15 headache days per month with ≥ 8 monthly migraine days (MMD). HFEM = High frequent episodic migraine is defined as ≥1 month with ≥ 8 MMD. LFEM = Low frequent episodic migraine is defined as < 8 MMD. MOH = Medication Overuse Headache is defined as ≥ 3 consecutive months with ≥ 15 headache days per month with either ≥ 15 days with use of analgesics/NSAIDS, or ≥ 10 triptan days, or ≥ 10 combined acute medication days.12 Evaluating missing criteria in days defined by triptan intake alone Days defined by triptan intake only missed ≥ 1 of the migraine characteristics, which is set out on the right side of Figure 1. In 66.6% (n=10,009) of these days the headache did not fulfill the duration of ≥ 4 hours. In 22.7% (n=3,409) the headache did not meet at least two of the four following headache features: unilateral; pulsating; moderate to severe pain; aggravation by activity. In 44.4% (n=6,666) no accompanying
RkJQdWJsaXNoZXIy MjY0ODMw